[1]
Contreras NA, Sabadell J, Verdaguer P, Julià C, Fernández-Montolí ME. Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions. International journal of molecular sciences. 2022 Feb 25:23(5):. doi: 10.3390/ijms23052531. Epub 2022 Feb 25
[PubMed PMID: 35269674]
Level 3 (low-level) evidence
[2]
Nees LK, Heublein S, Steinmacher S, Juhasz-Böss I, Brucker S, Tempfer CB, Wallwiener M. Endometrial hyperplasia as a risk factor of endometrial cancer. Archives of gynecology and obstetrics. 2022 Aug:306(2):407-421. doi: 10.1007/s00404-021-06380-5. Epub 2022 Jan 10
[PubMed PMID: 35001185]
[3]
Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Human reproduction update. 2017 Mar 1:23(2):232-254. doi: 10.1093/humupd/dmw042. Epub
[PubMed PMID: 27920066]
[4]
Shen Y, Yang W, Liu J, Zhang Y. Minimally invasive approaches for the early detection of endometrial cancer. Molecular cancer. 2023 Mar 17:22(1):53. doi: 10.1186/s12943-023-01757-3. Epub 2023 Mar 17
[PubMed PMID: 36932368]
[5]
Lathigara D, Kaushal D, Wilson RB. Molecular Mechanisms of Western Diet-Induced Obesity and Obesity-Related Carcinogenesis-A Narrative Review. Metabolites. 2023 May 21:13(5):. doi: 10.3390/metabo13050675. Epub 2023 May 21
[PubMed PMID: 37233716]
Level 3 (low-level) evidence
[6]
Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reproductive biomedicine online. 2009 Sep:19(3):398-405
[PubMed PMID: 19778486]
Level 1 (high-level) evidence
[7]
Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Mar 15:21(6):1180-9
[PubMed PMID: 12637488]
[8]
Lee M, Piao J, Jeon MJ. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen. Yonsei medical journal. 2020 Apr:61(4):317-322. doi: 10.3349/ymj.2020.61.4.317. Epub
[PubMed PMID: 32233174]
[9]
Lancaster JM, Powell CB, Chen LM, Richardson DL, SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic oncology. 2015 Jan:136(1):3-7. doi: 10.1016/j.ygyno.2014.09.009. Epub 2014 Sep 17
[PubMed PMID: 25238946]
[10]
Ryan NAJ, McMahon R, Tobi S, Snowsill T, Esquibel S, Wallace AJ, Bunstone S, Bowers N, Mosneag IE, Kitson SJ, O'Flynn H, Ramchander NC, Sivalingam VN, Frayling IM, Bolton J, McVey RJ, Evans DG, Crosbie EJ. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. PLoS medicine. 2020 Sep:17(9):e1003263. doi: 10.1371/journal.pmed.1003263. Epub 2020 Sep 17
[PubMed PMID: 32941469]
Level 2 (mid-level) evidence
[11]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: a cancer journal for clinicians. 2022 Jan:72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12
[PubMed PMID: 35020204]
[12]
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: a cancer journal for clinicians. 2023 Jan:73(1):17-48. doi: 10.3322/caac.21763. Epub
[PubMed PMID: 36633525]
[13]
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet (London, England). 2016 Mar 12:387(10023):1094-1108. doi: 10.1016/S0140-6736(15)00130-0. Epub 2015 Sep 6
[PubMed PMID: 26354523]
[14]
Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982 Jun 15:49(12):2547-59
[PubMed PMID: 7074572]
[15]
Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecologic oncology. 2012 May:125(2):477-82. doi: 10.1016/j.ygyno.2012.01.003. Epub 2012 Jan 11
[PubMed PMID: 22245711]
Level 1 (high-level) evidence
[16]
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2:497(7447):67-73. doi: 10.1038/nature12113. Epub
[PubMed PMID: 23636398]
[17]
Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15:106(4):812-9
[PubMed PMID: 16400639]
[18]
Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial cancer. Nature reviews. Disease primers. 2021 Dec 9:7(1):88. doi: 10.1038/s41572-021-00324-8. Epub 2021 Dec 9
[PubMed PMID: 34887451]
[19]
White K, Potter JE, Hopkins K, Fernández L, Amastae J, Grossman D. Contraindications to progestin-only oral contraceptive pills among reproductive-aged women. Contraception. 2012 Sep:86(3):199-203. doi: 10.1016/j.contraception.2012.01.008. Epub 2012 Feb 24
[PubMed PMID: 22364816]
[20]
Ring KL, Mills AM, Modesitt SC. Endometrial Hyperplasia. Obstetrics and gynecology. 2022 Dec 1:140(6):1061-1075. doi: 10.1097/AOG.0000000000004989. Epub 2022 Nov 2
[PubMed PMID: 36357974]
[21]
Doherty MT, Sanni OB, Coleman HG, Cardwell CR, McCluggage WG, Quinn D, Wylie J, McMenamin ÚC. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PloS one. 2020:15(4):e0232231. doi: 10.1371/journal.pone.0232231. Epub 2020 Apr 28
[PubMed PMID: 32343732]
Level 1 (high-level) evidence
[22]
Giri SK, Nayak BL, Mohapatra J. Thickened Endometrium: When to Intervene? A Clinical Conundrum. Journal of obstetrics and gynaecology of India. 2021 Jun:71(3):216-225. doi: 10.1007/s13224-020-01415-4. Epub 2021 Feb 2
[PubMed PMID: 34408340]
[23]
Vitale SG, Buzzaccarini G, Riemma G, Pacheco LA, Di Spiezio Sardo A, Carugno J, Chiantera V, Török P, Noventa M, Haimovich S, De Franciscis P, Perez-Medina T, Angioni S, Laganà AS. Endometrial biopsy: Indications, techniques and recommendations. An evidence-based guideline for clinical practice. Journal of gynecology obstetrics and human reproduction. 2023 Jun:52(6):102588. doi: 10.1016/j.jogoh.2023.102588. Epub 2023 Apr 13
[PubMed PMID: 37061093]
Level 1 (high-level) evidence
[24]
Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2004 Oct:24(5):558-65
[PubMed PMID: 15386607]
[25]
Ben-Baruch G, Seidman DS, Schiff E, Moran O, Menczer J. Outpatient endometrial sampling with the Pipelle curette. Gynecologic and obstetric investigation. 1994:37(4):260-2
[PubMed PMID: 8050731]
[26]
Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000 Oct 15:89(8):1765-72
[PubMed PMID: 11042572]
Level 1 (high-level) evidence
[27]
Dueholm M, Hjorth IMD, Dahl K, Ørtoft G. Hysteroscopic resectoscope-directed biopsies and outpatient endometrial sampling for assessment of tumor histology in women with endometrial cancer or atypical hyperplasia. European journal of obstetrics, gynecology, and reproductive biology. 2020 Aug:251():173-179. doi: 10.1016/j.ejogrb.2020.05.010. Epub 2020 May 11
[PubMed PMID: 32505790]
[28]
Bedner R, Rzepka-Górska I. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women. European journal of gynaecological oncology. 2007:28(5):400-2
[PubMed PMID: 17966221]
Level 2 (mid-level) evidence
[29]
Vitale SG, Riemma G, Carugno J, Chiofalo B, Vilos GA, Cianci S, Budak MS, Lasmar BP, Raffone A, Kahramanoglu I. Hysteroscopy in the management of endometrial hyperplasia and cancer in reproductive aged women: new developments and current perspectives. Translational cancer research. 2020 Dec:9(12):7767-7777. doi: 10.21037/tcr-20-2092. Epub
[PubMed PMID: 35117379]
Level 3 (low-level) evidence
[30]
Hwang WY, Suh DH, Kim K, No JH, Kim YB. Aspiration biopsy versus dilatation and curettage for endometrial hyperplasia prior to hysterectomy. Diagnostic pathology. 2021 Jan 14:16(1):7. doi: 10.1186/s13000-020-01065-0. Epub 2021 Jan 14
[PubMed PMID: 33441173]
[31]
Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, Glass AG, Richesson DA, Chatterjee N, Langholz B. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Feb 10:28(5):788-92. doi: 10.1200/JCO.2009.24.1315. Epub 2010 Jan 11
[PubMed PMID: 20065186]
[32]
Fang F, Xu H, Wu L, Hu L, Liu Y, Li Y, Zhang C. LNG-IUS combined with progesterone ameliorates endometrial thickness and pregnancy outcomes of patients with early-stage endometrial cancer or atypical hyperplasia. American journal of translational research. 2021:13(5):5412-5419
[PubMed PMID: 34150138]
[33]
Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. American journal of obstetrics and gynecology. 2010 Dec:203(6):547.e1-10. doi: 10.1016/j.ajog.2010.07.037. Epub
[PubMed PMID: 20934679]
Level 1 (high-level) evidence
[34]
Uccella S, Zorzato PC, Dababou S, Bosco M, Torella M, Braga A, Frigerio M, Gardella B, Cianci S, Laganà AS, Franchi MP, Garzon S. Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. Medicina (Kaunas, Lithuania). 2022 Sep 11:58(9):. doi: 10.3390/medicina58091256. Epub 2022 Sep 11
[PubMed PMID: 36143933]
[35]
Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Human reproduction (Oxford, England). 2013 Nov:28(11):2966-71. doi: 10.1093/humrep/det320. Epub 2013 Aug 23
[PubMed PMID: 23975691]
Level 2 (mid-level) evidence
[36]
Atak Z, Rahımlı Ocakoğlu S, Ocakoğlu G. Levonorgestrel-releasing intrauterine device to treat abnormal uterine bleeding; not one treatment option fits all. Journal of the Turkish German Gynecological Association. 2023 Dec 6:24(4):246-251. doi: 10.4274/jtgga.galenos.2023.2022-12-12. Epub
[PubMed PMID: 38054416]
Level 2 (mid-level) evidence
[37]
Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: an evaluation of current practice. European journal of obstetrics, gynecology, and reproductive biology. 2006 Apr 1:125(2):259-64
[PubMed PMID: 16246481]
[38]
Vieira-Serna S, Peralta J, Viveros-Carreño D, Rodriguez J, Feliciano-Alfonso JE, Pareja R. Sentinel lymph node assessment in patients with atypical endometrial hyperplasia: a systematic review and meta-analysis. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2023 Nov 16:():. pii: ijgc-2023-004936. doi: 10.1136/ijgc-2023-004936. Epub 2023 Nov 16
[PubMed PMID: 37973363]
Level 1 (high-level) evidence
[39]
Travaglino A, Raffone A, Saccone G, Mascolo M, Guida M, Mollo A, Insabato L, Zullo F. Congruence Between 1994 WHO Classification of Endometrial Hyperplasia and Endometrial Intraepithelial Neoplasia System. American journal of clinical pathology. 2020 Jan 1:153(1):40-48. doi: 10.1093/ajcp/aqz132. Epub
[PubMed PMID: 31433834]
[40]
Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Cummings M, Chen C, Leung Y, Sykes P, McNally O, Oehler MK, Walker G, Garrett A, Tang A, Land R, Nicklin JL, Chetty N, Perrin LC, Hoet G, Sowden K, Eva L, Tristram A, Obermair A. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecologic oncology. 2021 Apr:161(1):143-151. doi: 10.1016/j.ygyno.2021.01.029. Epub
[PubMed PMID: 33762086]
Level 1 (high-level) evidence
[41]
Ga H, Taguchi A, Honjoh H, Nishijima A, Eguchi S, Miyamoto Y, Sone K, Mori M, Osuga Y. Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy. Archives of gynecology and obstetrics. 2023 Nov:308(5):1629-1634. doi: 10.1007/s00404-023-07077-7. Epub 2023 Jun 13
[PubMed PMID: 37310452]